SG Americas Securities LLC Has $1.52 Million Stock Holdings in Krystal Biotech, Inc. $KRYS

SG Americas Securities LLC decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 68.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 5,899 shares of the company’s stock after selling 13,010 shares during the quarter. SG Americas Securities LLC’s holdings in Krystal Biotech were worth $1,524,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of KRYS. Sound Income Strategies LLC raised its holdings in Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after acquiring an additional 127 shares during the period. Greenline Wealth Management LLC bought a new stake in shares of Krystal Biotech during the fourth quarter worth approximately $34,000. Danske Bank A S bought a new stake in shares of Krystal Biotech during the third quarter worth approximately $35,000. UMB Bank n.a. grew its position in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after purchasing an additional 142 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,642 shares of company stock worth $8,243,923 in the last 90 days. 13.10% of the stock is owned by company insiders.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $375.07 on Friday. The business’s 50 day simple moving average is $312.90 and its 200 day simple moving average is $280.73. Krystal Biotech, Inc. has a 1 year low of $130.50 and a 1 year high of $382.54. The company has a market capitalization of $11.06 billion, a P/E ratio of 50.14 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. TD Cowen boosted their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Wolfe Research started coverage on Krystal Biotech in a report on Friday, March 27th. They issued a “peer perform” rating on the stock. HC Wainwright increased their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Finally, Evercore reissued an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and an average price target of $340.56.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.